$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

2017-12-21

2020-05-07

2020-05-07

23

Study Overview

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

N/A

  • Breast Cancer
  • Pancreas Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colon Cancer
  • Esophagus Cancer
  • Liver Cancer
  • Ovary Cancer
  • Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
  • DRUG: NP-G2-044
  • NP-G2-044-P1-01

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2017-06-23  

N/A  

2025-07-16  

2017-06-26  

N/A  

2025-07-20  

2017-06-27  

N/A  

2020-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: NP-G2-044

capsule

DRUG: NP-G2-044

  • capsule
Primary Outcome MeasuresMeasure DescriptionTime Frame
Establish the safe recommended phase 2 doseTreatment related adverse events assessed by CTCAE V4.0324 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Identify and characterize preliminary anti tumor activityAnti tumor activity assessed using RECIST 1.124 months
Characterize the pharmacokinetics of NP-G2-044Drug exposure assessed by area under the curve (AUC)24 months
TmaxTime to peak plasma concentration24 months
CmaxPeak plasma concentration24 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Signed informed consent and mental capability to understand the informed consent 2. Male or female patients > 18 years of age 3. Histologically or cytologically documented locally advanced or metastatic solid tumor malignancies either treatment-refractory or otherwise ineligible for treatment with standard-of-care agents/regimens 4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 5. Evaluable or measurable disease per RECIST v1.1 6. Life expectancy > 3 months 7. ECG without evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the Investigator 8. Acceptable organ and marrow function as defined below:

  • Absolute neutrophil count > 1,500 cells/μL
  • Hemoglobin ≥ 9.0 g/dL
  • Platelets > 100,000 cells/μL
  • Total bilirubin ≤ 1.5 mg/dL
  • Albumin ≥ 3 g/dL
  • Aspartate aminotransferase (AST)/alanine transaminase (ALT)/alkaline phosphatase (ALP)/Gamm-glutamyl transferase (GGT) ≤ 2.5 times ULN. For Phase 1A only, if liver metastases are present, AST/ALT/ALP < 5 times ULN
  • Serum creatinine < 1.5 mg./dL and a measured creatinine clearance ≥ 60 mL/min
  • Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times ULN 9. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test prior to first dose of study drug. 10. Male and female patients with reproductive potential must agree to use adequate contraceptive precautions throughout the study.

    • Exclusion Criteria:
    1. Chemotherapy, radiotherapy or other anti-cancer treatment within 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) of the first dose of study drug or patients who in opinion of Investigator have not recovered from AEs due to agents administered greater than 4 weeks earlier (prior immunotherapy is allowed) 2. Participation in any other clinical investigation using an experimental drug within 4 weeks of first dose of study drug 3. Failure to recover to ≤ grade 1 toxicity (except grade 1-2 alopecia or neuropathy) associated with previous chemotherapy, radiotherapy, biologic, hormone or prior investigational therapy 4. Known untreated brain metastases or treated brain metastases that have not been radiographically and clinically stable (i.e. not requiring steroids) ≥ 4 weeks prior to study enrollment 5. Baseline prolongation of QT/QTc interval (QTc interval > 470 msec in women and >450 msec in men) 6. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in opinion of Investigator would limit compliance with study requirements 7. Women who are pregnant or breastfeeding 8. Prior allogenic hematopoietic stem cell transplant or allogenic bone marrow transplant or prior solid organ transplant or current use of immuno suppression drugs or anti-transplant rejection drugs 9. Prior history of clinically significant gastrointestinal bleeding, intestinal obstruction or gastrointestinal perforation within 6 months of study enrollment 10. Sponsor reserves right to exclude any patient from the study on basis of pre-study medical histories, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • Translational Drug Development
  • STUDY_DIRECTOR: Jillian Zhang, Ph.D., Novita Pharmaceuticals

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Sever S. Role of actin cytoskeleton in podocytes. Pediatr Nephrol. 2021 Sep;36(9):2607-2614. doi: 10.1007/s00467-020-04812-z. Epub 2020 Nov 13.
NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate